<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Methylation-specific multiple ligation-dependent probe amplification (MS-MLPA) is a fast, new, inexpensive method that has rarely been exploited in DNA methylation profiling of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to test the diagnostic utility of MS-MLPA to evaluate the methylation status of 34 genes in <z:mpath ids='MPATH_458'>normal</z:mpath> colonic mucosa samples and in a well-characterized series of 83 <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and 21 neuroendocrine <z:mp ids='MP_0002038'>carcinomas</z:mp> of colon-rectum </plain></SENT>
<SENT sid="2" pm="."><plain>Two commercial MS-MLPA kits (SALSA MS-MLPA ME001-C1 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> suppressor-1 Kit and SALSA MS-MLPA ME002-B1 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> suppressor-2 Kit) were used to perform promoter methylation analysis on formalin-fixed and paraffin-embedded tissues </plain></SENT>
<SENT sid="3" pm="."><plain>MS-MLPA analysis was validated by <z:chebi fb="0" ids="17137">bisulfite</z:chebi> pyrosequencing, <z:chebi fb="0" ids="17137">bisulfite</z:chebi> cycle sequencing, and methylation-specific PCR </plain></SENT>
<SENT sid="4" pm="."><plain>MS-MLPA analysis identified a subset of 27 CRCs (26 % of cases) showing high levels of gene methylation involving a mean percentage of 34 % of the promoters examined </plain></SENT>
<SENT sid="5" pm="."><plain>These <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> exhibited <z:hpo ids='HP_0000001'>all</z:hpo> the main clinicopathological and genetic features described for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> with CpG island Methylator Phenotype-High </plain></SENT>
<SENT sid="6" pm="."><plain>High levels of methylation were observed with similar frequency in <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and in neuroendocrine <z:mp ids='MP_0002038'>carcinomas</z:mp> (25 % versus 29 %, respectively), but different methylation profiles were observed in the two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
<SENT sid="7" pm="."><plain>In both groups, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with microsatellite instability and widespread methylation represented a homogeneous clinicopathological entity </plain></SENT>
<SENT sid="8" pm="."><plain>MS-MLPA assay is an easy and reliable system for epigenetic characterization of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues and leads to a rapid identification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> with the highest levels of gene methylation </plain></SENT>
<SENT sid="9" pm="."><plain>Aberrant gene methylation is a common abnormality in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> initiation and may be observed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with very different genetic and clinicopathological profiles </plain></SENT>
</text></document>